Still A COVID-19 Game Changer? UK’s Cautious Launch Of MSD’s Antiviral Lagevrio

Efficacy In Vaccinated Population Unproven

The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.  

UK oovid December 2021
The Lagevrio study coincides with the UK re-introducing social distancing measures to limit the effects of the new Omicron variant. • Source: Getty Images

The UK government has begun the roll-out of MSD’s Lagevrio (molnupiravir), the first oral antiviral treatment for COVID-19, but is taking a cautious approach to its use amid signs it may not be the ‘game changer’ that was initially hoped.

The government has decided to recruit 10,000 at-risk individuals to a trial of Lagevrio to gather further data following uncertainties...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D